Literature DB >> 8961504

International bank for foot-and-mouth disease vaccine: assessment of Montanide ISA 25 and ISA 206, two commercially available oil adjuvants.

P V Barnett1, L Pullen, L Williams, T R Doel.   

Abstract

The International Vaccine Bank at Pirbright has recently installed large-scale vaccine formulation equipment for the preparation of oil-adjuvanted vaccines. Such vaccines are claimed to offer a number of advantages over Al(OH)3, particularly their ability to raise better immunity in pigs. This paper reports on the potency in pigs, cattle and guinea-pigs of foot-and-mouth disease vaccines prepared with two novel oil adjuvants, Montanide ISA 25 and 206 (Seppic, Paris). The results indicate that vaccines adjuvanted with these oils retain potency for a longer period than our conventional aqueous formulation, following storage at +4 degrees C, and elicit good antibody responses in both pigs and cattle regardless of injection route. In addition they gave no evidence of toxicity or prolonged pyrexia following their administration. Local reactions at the site of inoculation were not observed in cattle vaccinated intramuscularly, even following a booster dose. Pigs vaccinated intramuscularly only showed local reactions if the volume administered exceeded the 2.0 ml dose or the animals received a second vaccination. These observations on the efficacy of such oil formulated vaccines suggest that they have potential as an alternative to the current aqueous formulation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961504     DOI: 10.1016/s0264-410x(96)00055-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Foot and mouth disease: a revised policy is required.

Authors:  J Bayry; S V Kaveri
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Vaccination against foot-and-mouth disease: the implications for Canada.

Authors:  Sarah Kahn; Dorothy W Geale; Paul R Kitching; Alice Bouffard; Denis G Allard; J Robert Duncan
Journal:  Can Vet J       Date:  2002-05       Impact factor: 1.008

3.  Immune responses of sheep to quadrivalent double emulsion foot-and-mouth disease vaccines: rate of development of immunity and variations among other ruminants.

Authors:  Prasanna K Patil; Jagadeesh Bayry; Chitimalla Ramakrishna; Basavesh Hugar; Laxmi D Misra; Krishnamsetty Prabhudas; C Natarajan
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

5.  Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine.

Authors:  Jun-Jun Shao; Chung Kai Wong; Tong Lin; Shuk Kwan Lee; Guo-Zheng Cong; Fion Wai Yee Sin; Jun-Zheng Du; Shan-Dian Gao; Xiang-Tao Liu; Xue-Peng Cai; Yong Xie; Hui-Yun Chang; Ji-Xing Liu
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

Review 6.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

7.  Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide.

Authors:  Carolina Cubillos; Beatriz G de la Torre; Annamaria Jakab; Giorgia Clementi; Eva Borrás; Juan Bárcena; David Andreu; Francisco Sobrino; Esther Blanco
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

8.  Lysine: Is it worth more?

Authors:  D Datta; A Bhinge; V Chandran
Journal:  Cytotechnology       Date:  2001-07       Impact factor: 2.058

Review 9.  Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: a review.

Authors:  Sarah J Cox; Paul V Barnett
Journal:  Vet Res       Date:  2008-12-02       Impact factor: 3.683

10.  Requirements for improved vaccines against foot-and-mouth disease epidemics.

Authors:  Jong-Hyeon Park
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.